Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Roche and Gilead Launch COVID-19 Trial to Test One-Two Punch of Actemra and Remdesivir
BioSpace
Thu, 05/28/20 - 10:59 pm
Tags:
Roche, Gilead Sciences, clinical trials, Actemra, RoActemra, remdesivir, COVID-19, pneumonia, COVID-19 pneumonia
UK grants early access for Gilead’s remdesivir in Covid-19
MedCity News
Thu, 05/28/20 - 10:37 am
Tags:
UK, Gilead Sciences, remdesivir, COVID-19
Gilead pens $2B Arcus pact for immuno-oncology targets of the past and future
Fierce Biotech
Wed, 05/27/20 - 10:28 am
Tags:
Gilead Sciences, ARCUS, immuno-oncology
Bangladesh pharma claims to be first to launch generic remdesivir
BioPharma Dive
Thu, 05/21/20 - 11:08 pm
Tags:
Bangladesh, Beximco, generics, remdesivir, Gilead Sciences, COVID-19
Gilead's filgotinib phase 3 hits primary endpoint but details dampen hopes
Fierce Biotech
Thu, 05/21/20 - 10:28 am
Tags:
Gilead Sciences, Galapagos, filgotinib, ulcerative colitis, clinical trials
Covid-19 has exposed the limits of the pharmaceutical market model
Stat
Wed, 05/20/20 - 11:26 pm
Tags:
pharma marketing, Gilead Sciences, remdesivir, COVID-19, drug development, pandemics
Big pharma heads towards important readouts
EP Vantage
Wed, 05/20/20 - 10:22 am
Tags:
Ozempic, Novo Nordisk, etrolizumab, Roche, Ipatasertib, finerenone, Bayer, filgotinib, Gilead Sciences, Galapagos, Avalglucosidase alfa, Sanofi, Rinvoq, AbbVie, clinical trials
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Endpoints
Tue, 05/19/20 - 10:33 am
Tags:
GSK, Gilead Sciences, HIV, PrEP, Truvada, ViiV Healthcare, cabotegravir
Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals
Stat
Mon, 05/18/20 - 11:09 pm
Tags:
Gilead Sciences, COVID-19, remdesivir, federal government
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
Fierce Pharma
Mon, 05/18/20 - 11:12 am
Tags:
GSK, Gilead Sciences, Truvada, cabotegravir, HIV, PrEP
Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be
Motley Fool
Mon, 05/18/20 - 11:10 am
Tags:
Gilead Sciences, remdesivir, COVID-19
Where Will Gilead Sciences Be in 1 Year?
Motley Fool
Wed, 05/13/20 - 11:15 am
Tags:
Gilead Sciences, remdesivir, COVID-19, pandemic
Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries
Fierce Pharma
Tue, 05/12/20 - 05:16 pm
Tags:
Gilead Sciences, generics, drug manufacturing, COVID-19, remdesivir
With little data, doctors struggle to decide which Covid-19 patients should get remdesivir
Stat
Tue, 05/12/20 - 12:05 pm
Tags:
Gilead Sciences, remdesivir, physicians, pandemic, patients, COVID-19
Inside the NIH’s controversial decision to stop its big remdesivir study
Stat
Mon, 05/11/20 - 10:24 am
Tags:
Gilead Sciences, remdesivir, NIH, clinical trials, COVID-19, pandemic
Trump administration: States to decide which hospitals gets Gilead's COVID-19 drug
BioPharma Dive
Mon, 05/11/20 - 10:12 am
Tags:
Donald Trump, pandemic, Gilead Sciences, remdesivir, COVID-19
Gilead hit with Iranian cyberattack for role in COVID-19 response: report
Fierce Pharma
Sun, 05/10/20 - 12:05 am
Tags:
Gilead Sciences, cybersecurity, cyberhacking, Iran, COVID-19, pandemic
Early missteps, transparency questions dog U.S. government's remdesivir rollout: reports
Fierce Pharma
Sun, 05/10/20 - 12:03 am
Tags:
Gilead Sciences, FDA, remdesivir, pandemic, COVID-19
The U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit
Stat
Fri, 05/8/20 - 10:29 am
Tags:
Gilead Sciences, remdesivir, federal government, patents, R&D
Japan approves Gilead Sciences' remdesivir as COVID-19 drug
Reuters
Thu, 05/7/20 - 10:32 pm
Tags:
Japan, Gilead Sciences, COVID-19, remdesivir

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.